Overview
DNTH market data
Price History
DNTH price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$4.20 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.86 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -10,097.0% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $19.00 – $114.55 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $6.2B · P/B 3.58 · P/S 3,253.54.
Company News
Truist Securities Maintains Buy on Dianthus Therapeutics, Raises Price Target to $128Benzinga · Aug 6, 2026, 3:55 PM
HC Wainwright & Co. Maintains Buy on Dianthus Therapeutics, Raises Price Target to $158Benzinga · Aug 6, 2026, 11:01 AM
Wedbush Maintains Outperform on Dianthus Therapeutics, Raises Price Target to $122Benzinga · Aug 5, 2026, 1:22 PM
Dianthus Therapeutics Q2 EPS $(0.90) Misses $(0.88) Estimate, Sales $761.000K Beat $258.583K EstimateBenzinga · Aug 4, 2026, 8:21 PM
Dianthus Therapeutics Announces New Pipeline Candidate, DNTH312 for Autoimmune Disorders; The Company Expects DNTH312 to be Phase 1 Ready By End Of 2027Benzinga · Aug 4, 2026, 11:10 AM
Dianthus Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)Globenewswire Inc · Aug 3, 2026, 10:15 PM
Evercore ISI Group Maintains Outperform on Dianthus Therapeutics, Raises Price Target to $134Benzinga · Aug 3, 2026, 3:03 PM
Why Is Dianthus Therapeutics Stock Trading Higher On Friday?Benzinga · Jun 12, 2026, 5:25 PM
8-K filing — Dianthus Therapeutics, Inc. /DE/ (DNTH)SEC EDGAR · Jun 12, 2026, 11:00 AM
Sanofi Trial Setback May Reinforce Argenx Vyvgart's Position In CIDP, Analyst SaysBenzinga · Jun 11, 2026, 2:30 PM